Ozempic Significantly Lowers Death Risk in Diabetics with Kidney Disease, Study Shows
TL;DR Summary
A major study has found that Ozempic's active compound, semaglutide, significantly reduces the risk of death from chronic kidney disease by 24%, potentially expanding its use. The study, funded by Novo Nordisk and involving 3,533 patients, was so conclusive that it was stopped early, impacting dialysis company shares.
- Ozempic cuts risk of death from kidney disease, major study finds The Washington Post
- Novo unveils full results from its GLP-1 trial in CKD FiercePharma
- Ozempic reduces risk of serious illness and death in people with diabetes and kidney disease, study finds CNN
- Novo Nordisk’s Semaglutide Cuts Death Risk in Diabetics with CKD in Phase III Trial BioSpace
- Ozempic May Help Treat Kidney Disease, Study Finds The New York Times
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
0 min
vs 1 min read
Condensed
63%
129 → 48 words
Want the full story? Read the original article
Read on The Washington Post